Seoul Economic Daily EnglishQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 15:00:12(首尔 16:00)·⟳ 抓取 15:10:32 +10m20s·⚡ 决策 09-14 15:16:50 +6m18s·43.2 天前
SK Biopharmaceuticals（326030.KS）向美国子公司 SK Life Science 供应 716 亿韩元 cenobamate，属常规集团内供货、合并报表不确认收入
内部 KB 的 DART 原始披露证明这是近乎月度重复的母子公司关联交易（7/28、8/18、9/14 三笔同结构），本次金额还低于前两笔，且原文明确合并报表不确认收入——既无收入/利润/指引增量，也无美国终端需求加速的可验证读数；自家案例库显示同一公告已两次判『不做』且从未在该票 ENTER。韩股 16:13 已收盘，当日亦无可执行窗口。故给 AVOID，不输出风险行（事件非净利空）。
📄 原文Seoul Economic Daily English↗ 原文
SK Biopharmaceuticals Supplies 71.6 Billion Won of Cenobamate to U.S. Unit
Seoul Economic Daily Skip to main content Seoul Economic Daily Seoul Economic Daily KST Seoul Economic Daily Korea's Le…
不做 SK Biopharmaceuticals（326030.KS）
与全资美国子公司 SK Life Science 的 716 亿韩元、期限 5 天供货合同属例行关联交易，合并报表不确认收入，且规模低于 7/28（811 亿）与 8/18（994 亿）两笔同结构披露，无任何收入/利润/指引增量，也无终端需求加速读数；韩股 9/14 16:13 已收盘，当日无可执行窗口；股价处 13 周下行轨迹（-45% 距 52 周高），做多无 edge，事件本身非净利空亦不满足做空红线，故不做。
不做 SK Inc.（034730.KS）
仅为 SK Biopharmaceuticals 的控股母公司，子公司零增量的内部供货调拨不改变其合并盈利或估值锚，无因果敞口，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
这是一份金额 716 亿韩元、期限仅 5 天、对手方为全资美国子公司的例行内部供货公告，合并口径不确认收入，且规模小于 7 月与 8 月两笔同结构合同。既无财务增量也无需求信号，方向中性，A股/港股无可映射的二阶受益方，判定不做。
消息传播链
- 公司以监管披露形式发布，属程序性关联交易公告；本轮未取得 9/14 该笔的 DART 原始链接，首发事实依据为媒体转述，标注为非一手节点。
- 英文媒体在披露当日同步报道并明确指出『合并口径不确认收入』，本身即否定其催化属性；未见其它主流媒体跟进。
- 2026-09-14 16:13 KST市场反应行情工具（yfinance 日线）非一手公告发生在韩股收盘后，当日 326030.KS 收 79,100 韩元、-0.38%，量比 0.8，无任何异动，市场未将其视为新信息。
关键理由
- 关联交易在合并层面全额抵消，10.1% 的营收占比只是单体口径披露，不产生任何新增可确认收入或利润。
- 同结构披露在 7/28（811 亿韩元）与 8/18（994 亿韩元）已出现，本次 716 亿韩元环比下降，连『出货量加速』这一软读数也不成立。
主要风险
- 若后续披露显示美国 XCOPRI 终端处方量或 SK Life Science 对外销售明显走弱，则该股（当前距 52 周高 -45%、20 日 -9.4%、13 周轨迹持续下行）的下行趋势可能延续，但那是财报/处方数据事件，与本条公告无关。
- 本判断依赖 Seoul Economic Daily 英文版对 DART 公告的 AI 翻译转述；未能直接调取 9/14 当日 DART 原文（rcpNo 未知），但同类原文两笔已在内部 KB 命中且结构一致。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-08-18 · 影响 invalidates
内部 KB 命中 7/28 与 8/18 两笔同结构 DART 原文，证明该披露高频重复且金额本次反而下降，『订单=需求加速』的做多逻辑被直接证伪。
检索:SK Biopharmaceuticals cenobamate XCOPRI 美国销售 需求 加速 / 关联交易 供货合同 重复 原文 ↗ - 做多前查反向 · 来源 stock_quote · 日期 2026-09-14 · 影响 weakens
13 周指数化轨迹 100→89 持续下行，近 5 日 -2.1/+0.7/-0.5/-4.8/-0.4，9/11 单日 -4.8%，公告日量比 0.8、收 -0.38%；无抢跑也无正向承接，属『一直阴跌』形态，低位本身不构成做多理由。
检索:326030.KS 近期股价轨迹与公告日异动（抢跑/泄露检查） - 做空前查反向 · 来源 kb_search · 日期 2026-09-14 · 影响 none
公告本身是正常的内部货物调拨，无负面条款、无减值、无指引下调，未通过『事实性净损害』测试；股价近月下跌由既有基本面/情绪因素驱动，不能由本事件生成风险行或做空腿。
检索:SK Biopharmaceuticals 关联交易 供货合同 是否构成公司级净利空 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例研究未改变结论，只强化了『程序性关联交易无 edge』的判断，最终标的与仓位均维持不做。
方向:无可测事件反应可参考：同一主体同结构关联交易近两月已重复三次，属无信息量的例行披露。
涨幅量级:不做幅度校准；本次金额 716 亿韩元低于 7/28 的 811 亿与 8/18 的 994 亿，且合并抵消，对每股盈利增量为零。
形态:自家案例库显示 7/28 与 8/18 两笔同类披露我们均判『不做』，326030.KS / 034730.KS 历史上从未 ENTER；股价在 8/18 披露后一个月内仍从约 87,000 韩元区间跌至 79,100 韩元，说明此类公告既不推动上涨也无支撑作用。
工具执行结果 · 成功 6 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 85 ms
{"result": "search_processed_events:agent query=`71.6 billion won xcopri intercompany supply | sk biopharmaceuticals cenobamate supply contract sk life science | sk biopharmaceuticals epilepsy drug us subsidiary supply filing | s`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - fetch_decision_experience 成功 stock_tools HTTP · 40 ms
{ - web_search 成功 Bing RSS · 334 ms
Bing RSS 搜索结果（原始查询:SK바이오팜 세노바메이트 SK라이프사이언스 공급계약 공시 단일판매） - web_search 成功 Bing RSS · 281 ms
Bing RSS 搜索结果（原始查询:SK Biopharmaceuticals cenobamate supply contract SK Life Science regulatory filing intercompany won） - stock_quote 降级 stock_tools HTTP · 6,966 ms
{ - kb_search 成功 stock_tools HTTP · 2,522 ms
{ - search_case_library 成功 stock_tools HTTP · 141 ms
{"result": "search_case_library「034730.KS,326030.KS」—— 与这些标的相关、事件类型=订单/中标/供货的自家决策案例(本页 7 条,该标的全历史相关记录共 51 条；ENTER 只按该标的自己的腿统计):\n◆ 034730.KS：相关历史决策 32 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n◆ 326030.KS：相关历史决策 19 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标
原文全文
展开原文 · 3,540 字
SK Biopharmaceuticals Supplies 71.6 Billion Won of Cenobamate to U.S. Unit - Seoul Economic Daily
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Interior view of SK Biopharmaceuticals' Pangyo headquarters. Photo courtesy of SK Biopharmaceuticals
SK Biopharmaceuticals (326030.KS) will supply about 71.6 billion won ($51.5 million) worth of cenobamate, its epilepsy drug sold under the brand name XCOPRI, to its U.S. subsidiary for sale in the American market.
The company said in a regulatory filing on the 14th that it had signed a pharmaceutical supply contract worth 71.59316 billion won with SK Life Science, its U.S. arm. The amount equals 10.1% of SK Biopharmaceuticals' consolidated revenue of 706.74096 billion won last year.
Under the contract, SK Biopharmaceuticals will supply the product to SK Life Science for sale in the U.S. market. The contract runs from that day through the 18th. There is no down payment or advance payment, and SK Life Science will pay within 120 days of delivery.
SK Life Science is SK Biopharmaceuticals' U.S. subsidiary and handles sales of cenobamate in the United States. Under the structure, SK Biopharmaceuticals develops and manufactures the drug while its U.S. unit sells it locally.
Because the transaction is an intercompany deal between SK Biopharmaceuticals and SK Life Science, however, it will not be recognized as revenue on a consolidated basis.
#
SKBiopharmaceuticals
#
Cenobamate
#
XCOPRI
#
SKLifeScience
#
Epilepsy
#
KoreaPharma
Original reporting by
Park Woo-in
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
Skip to main content
Seoul Economic Daily
Seoul Economic Daily
KST
Seoul Economic Daily
Korea's Leading Business News Since 1960
한국어
Menu
Saved Articles
Newsletters
AI KEY
Settings
|
Summary
|
Save
A
A
A
Interior view of SK Biopharmaceuticals' Pangyo headquarters. Photo courtesy of SK Biopharmaceuticals
SK Biopharmaceuticals (326030.KS) will supply about 71.6 billion won ($51.5 million) worth of cenobamate, its epilepsy drug sold under the brand name XCOPRI, to its U.S. subsidiary for sale in the American market.
The company said in a regulatory filing on the 14th that it had signed a pharmaceutical supply contract worth 71.59316 billion won with SK Life Science, its U.S. arm. The amount equals 10.1% of SK Biopharmaceuticals' consolidated revenue of 706.74096 billion won last year.
Under the contract, SK Biopharmaceuticals will supply the product to SK Life Science for sale in the U.S. market. The contract runs from that day through the 18th. There is no down payment or advance payment, and SK Life Science will pay within 120 days of delivery.
SK Life Science is SK Biopharmaceuticals' U.S. subsidiary and handles sales of cenobamate in the United States. Under the structure, SK Biopharmaceuticals develops and manufactures the drug while its U.S. unit sells it locally.
Because the transaction is an intercompany deal between SK Biopharmaceuticals and SK Life Science, however, it will not be recognized as revenue on a consolidated basis.
#
SKBiopharmaceuticals
#
Cenobamate
#
XCOPRI
#
SKLifeScience
#
Epilepsy
#
KoreaPharma
Original reporting by
Park Woo-in
for Seoul Economic Daily.
AI-translated from Korean. Quotes from foreign sources are based on Korean-language reports and may not reflect exact original wording.
Translated by AI on
Sep 14, 2026
View Korean original
↗
Translation Policy
Watch · Seoul Economic Daily
More →
2:20
KB Securities Sees Samsung Back at No.1, SK Hynix at No.3 Next Year | September 14 2026 | Securities Daily
2:20
Most Read This Week
1
-
5
‹
›
1
JBL Launches Xtreme 5 Bluetooth Speaker With Stronger Bass
2
Hyundai, POSCO Break Ground on $5.8 Billion U.S. Steel Mill
3
China Pumps 300 Billion Yuan Into Eight Financial Firms
4
Korea to Offer 20,000 Homes at 1,000 Won a Day for Young Adults
5
Samsung, SK hynix Memory Stockpiles Fall Below 10 Days
← Back to Home
AI KEY
Preview
↗
Korean Corporate Intelligence Hub
KOSPI · KOSDAQ · 12 sectors
A live, cap-weighted view of every KOSPI and KOSDAQ sector, with same-day Korean reporting distilled by company — built for foreign investors, correspondents and analysts who need to scan Korea before the next session.
Click to explore AI KEY
→
Open AI KEY in full screen
↗
Korea Company Atlas
Preview
↗
Market Ontology · The Feedback Loop
KFTC 2025 · 92 groups · 121,954 articles
An English ontology of the Korean market — how companies, the media, the government and the National Assembly move each other in a loop. Korea's named controlling persons and designated business groups are a mechanism, not a risk to be priced blind.
Click to explore the atlas
→
Open Atlas in full screen
↗
SIGNAL
Now live
↗
English Edition · Capital Markets
M&A · IPO · PE · Fund Flows
SIGNAL English Edition is live — Korea's deal desk reporting in English. M&A, IPOs, private equity and fund flows, covered daily for global institutional investors. Browse free; subscriber-only scoops at the 50% intro rate.
Click to explore SIGNAL
→
Open SIGNAL in full screen
↗
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。